Safety, Tolerability, and Pharmacokinetics of Single Ascending Doses of ELX‐02, a Potential Treatment for Genetic Disorders Caused by Nonsense Mutations, in Healthy Volunteers.

Autor: Leubitz, Andi1 (AUTHOR) andi@eloxxpharma.com, Frydman‐Marom, Anat1 (AUTHOR), Sharpe, Neal2 (AUTHOR), Duzer, John2 (AUTHOR), Campbell, Kathleen C.M.3 (AUTHOR), Vanhoutte, Frédéric4 (AUTHOR)
Zdroj: Clinical Pharmacology in Drug Development. Nov2019, Vol. 8 Issue 8, p984-994. 11p.
Databáze: Academic Search Ultimate
Nepřihlášeným uživatelům se plný text nezobrazuje